Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00784225 · ClinicalTrials.gov registry record · Phase 3
S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,475
- Enrollment target
NCT00784225 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 13,475 participants.
The verdict
NCT00784225, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,475 participants
- Enrollment target
Study Summary
RATIONALE: Aging may affect a person's vision. Vitamin E and/or selenium may help prevent cataracts or age-related macular degeneration in men receiving these drugs as part of a clinical trial for the prevention of prostate cancer. PURPOSE: This clinical trial is studying vitamin E and/or selenium to see how well they work in preventing cataract and age-related macular degeneration in men enrolled on SELECT (SWOG-S0000).
Interventions
- DRUG selenium
- DRUG vitamin E
- DRUG vitamin E placebo
- DRUG selenium placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,475 participants |
| Start Date | 2004-07 |
| Est. Completion | 2018-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00784225
The ClinicalTrials.gov registry entry for NCT00784225 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13,475 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which selenium is the first listed.
NCT00784225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00784225 about?
NCT00784225 is a clinical study titled "S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000". RATIONALE: Aging may affect a person's vision. Vitamin E and/or selenium may help prevent cataracts or age-related macular degeneration in men receiving these drugs as part of a clinical trial for the prevention of prostate cancer. PURPOSE: This clinical trial is studying vitamin E and/or selenium ...
What is the current status of trial NCT00784225?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,475 participants. The study started on 2004-07. Estimated completion is 2018-05.
What interventions are being tested in trial NCT00784225?
The interventions under investigation include: selenium (DRUG), vitamin E (DRUG), vitamin E placebo (DRUG), selenium placebo (DRUG).
Who is sponsoring clinical trial NCT00784225?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.